AsmussenV. (2006). On whose terms? User participation in Danish methadone maintenance treatment. In AnkerJ., AsmussenV., KouvonenP., & TopsD. (Eds.), Drug users and spaces for legitimate action. (pp. 205–226). Helsinki: Nordic Council for Alcohol and Drug Research.
2.
BaborT., SteniusK., & RomelsjöA. (2009). Päihdehuollon järjestelmät kansanterveyden näkökulmasta [Substance use treatment systems from a public health perspective]. In TammiT., AaltoM., & Koski-JännesA. (Eds.), Irti päihdeongelmista [Away from substance use problems]. (pp. 195–216). Porvoo: Edita.
3.
EkendahlM. (2011). The limits of legitimacy: Service providers' views on maintenance treatment in Sweden.Addiction Research & Theory,19(5), 427–437.
4.
EMCDDA (2011). Cost and financing of drug treatment services in Europe. An exploratory study.Lisbon: EMCDDA.
5.
EMCDDA (2012a). Sweden. 2012 National report (2011 data) to the EMCDDA.Lisbon: EMCDDA.
6.
EMCDDA (2013a). Statistical bulletin 2013. Table HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST). Part (i) Estimates of clients in methadone treatment or any opioid substitution in EU, Croatia, Turkey and Norway, 1993–2011. Retrieved from http//:www.emcdda.europa.eu
7.
EMCDDA (2012b). The drug situation in Norway 2012.Lisbon: EMCDDA. Retrieved from http//:www.emcdda.europa.eu
8.
EMCDDA (2013b). Statistical bulletin 2013. Problematic drug use (PDU) prevalence – an overview of the methods and definitions used. Retrieved from http//:www.emcdda.europa.eu
9.
EMCDDA (2013c). Statistical bulletin 2013. Table HSR-9. Opioid substitution treatment in prison in EU, Croatia, Turkey and Norway, 2010/2011. Retrieved from http//:www.emcdda.europa.eu
FugelstadA., Johansson,LA., ThiblinI. (2010). Allt fler dör av metadon. “Läckage” från dagens mer liberala behandlingsprogram kan vara en orsak [More and more deaths from methadone. Leakage from todays more liberal treatment programmes can be one cause].Läkartidningen,107(18), 1225–1228. Retrieved from http://www.lakartidningen.se/OldWebArticlePdf/1/14301/LKT1018s1225_1228.pdf
14.
Helsedirektoratet (2010). Nasjonal retningslinje for legemiddelassistert rehabilitering ved opioidavhengighet [National guidelines medication-assisted rehabilitation for opioid dependence]. Oslo: Helsedirektoratet. Retrieved from http://helsedirektoratet.no
15.
Helsedirektoratet (2013). Helsetjenester til innsatte i fengsel (Årsrapport 2012) [Inmate health care (Annual report)]. Oslo: Helsedirektoratet. Retrieved from http://helsedirektoratet.no
16.
HouborgE. (2012). The political pharmacology of methadone and heroin in Danish drug policy.Contemporary Drug Problems,39(Spring 2012), 155–192.
17.
KuljukkaL., NiskalaM., PartanenA., KuussaariK., & VormaH. (2013). Päihdepalveluihin pääsy suurissa kunnissa vuosina 2011 ja 2012 (Raportteja 38/2013) [Access to substance abuse services in large municipalities in 2011 and 2012 (Reports)]. Helsinki: Terveyden ja hyvinvoinnin laitos., Retrieved from http//:www.julkari.fi
18.
Kuusikko-työryhmä (2013). Kuuden suurimman kaupungin päihdehuollon palvelujen ja kustannusten vertailu vuonna 2012 (Kuusikko-työryhmän julkaisusarja 3/2013) [Comparison of substance abuse services and costs in the six largest city in 2012]. Helsinki: Edita.
19.
LauritzenG., RavndalE., & LarssonJ. (2012). Gjennom 10 år. En oppf⊘lgingsstudie av narkotikabrukere i behandling [Through 10 years. A follow-up study of drug users in treatment]. SIRUS-rapport nr. 6/2012. Oslo: Statens institutt forrusmiddelforskning.
20.
Läkemedelsassisterad behandling vid opiatberoende [Medication-assisted treatment in opioid dependence] 7.12.2009. SOSFS 2009:27 (M). Föreskrifter och allmänna råd [Regulations and guidelines]. Retrieved from http://www.socialstyrelsen.se/sosfs/2009-27
21.
OllgrenJ., ForsellM., VarjonenV., AlhoH., Brummer-KorvenkontioH., KainulainenH., KarjalainenK., KotovirtaE., PartanenA., RönkäS., SeppäläT., & VirtanenA. (2014). Amfetamiinien ja opioidien ongelmakäytön yleisyys Suomessa 2012 [Prevalence of amphetamine and opioid misuse in Finland in 2012].Yhteiskuntapolitiikka, 79, 498–508.
22.
PartanenA., VormaH., AlhoH., & LeppoA. (2014). Opioidiriippuvuuden lääkkeellinen vieroitus- ja korvaushoito Suomessa [Medicinal detoxification and substitution treatment of opioid dependence in Finland].Suomen Lääkärilehti,69(7), 481–486.
23.
PeräläR., HellmanM., & LeppoA. (2013). Behind the scenes. The justifications for opioid maintenance treatment in Finland.Substance Use & Misuse, 48(11), 954–965.
24.
PeterssonF. (2013). Excusing exclusion: Accounting for rule-breaking and sanctions in a Swedish methadone clinic.International Journal of Drug Policy,24, e99–e104.
25.
SelinJ., HakkarainenP., PartanenA., TammiT., & TigerstedtC. (2013). From political controversy to a technical problem? Fifteen years of opioid substitution treatment in Finland.International Journal of Drug Policy,24, e66–e72.
26.
SelinJ., PeräläR., SteniusK., PartanenA., RosenqvistP., & AlhoH. (2015). Opioidikorvaushoito Suomessa ja muissa Pohjoismaissa [Opioid substitution treatment in Finland and other Nordic countries].Suomen Lääkärilehti,70(19), 51–57.
27.
Simonsen,KW., Normann,PT., CederG., VuoriE., ThordardottirS., ThelanderG., RollmanD. (2011). Fatal poisoning in drug addicts in the Nordic countries in 2007.Forensic Science International, 207(1–3), 170–176.
28.
SkrettingA., & RosenqvistP. (2010). Shifting focus in substitution treatment in the Nordic countries.Nordic Studies on Alcohol and Drugs,27(6), 581–597.
29.
Socialstyrelsen (2012). Kartläggning av läkemedelsassisterad behandling vid opiatberoende. Socialstyrelsen. Retrieved from http://www.socialstyrelsen.se
30.
Socialstyrelsen (2015). Nationella riktlinjer för vård och stöd vid missbruk och beroende. Stöd för styrning och ledning [National care and support guidelines for substance misuse and dependence. Support for governance and management]. Socialstyrelsen. Retrieved from http//:www.socialstyrelsen.se
Sundhedsstyrelsen (2008). Guidance no. 42 on medical treatment of drug abusers in substitution treatment for opioid dependence.Copenhagen: Sundhedsstyrelsen. Retrieved from www.sundhedsstyrelsen.dk
33.
Sundhedsstyrelsen (2013a). Evaluering af ordning med lægeordineret heroin til stofmisbrugere (Statusrapport for perioden 2009–2011) [Evaluation of medically prescribed heroin to drug users]. Copenhagen: Sundhedsstyrelsen. Retrieved from http//:www.sundhedsstyrelsen.dk
34.
Sundhedsstyrelsen (2013b). Narkotikasituationen i Danmark 2013 [The drug situtation in Denmark 2013]. Copenhagen: Sundhedsstyrelsen. Retrieved from http//:www.sundhedsstyrelsen.dk
35.
TammiT. (2007). Medicalising prohibition. Harm reduction in Finnish and international drug policy. Stakes, research report 161. Helsinki: Stakes.
36.
ThomB., DukeK., AssmussenF., & BjargeB. (2013). Stakeholders in opioid substitution treatment policy: similarities and differences in six European countries.Substance Use & Misuse, 48(11), 933–42.
37.
UosukainenH., KauhanenJ., Bell,JS., RonkainenK., TiihonenJ., FöhrJ., Onyeka,IN., Korhonen,MJ. (2013). Mortality among clients seeking treatment for buprenorphine abuse in Finland.Drug and Alcohol Dependence,133, 391–397.
38.
VarjonenV., TanhuaH., & ForsellM. (2014). Huumetilanne Suomessa 2013 (Raportti 5/2014). Helsinki: Terveyden ja hyvinvoinnin laitos.
39.
WaalH., BussesundK., ClausenT., HåsethA., & LillevoldP.H. (2013). Statusrapport 2012. LAR som det vil bli fremover? (Seraf rapport 1/2013) [Status report 2012. The future of OMT]. Oslo: Senter for rus- og avhengighetsforskning, SERAF.
40.
WaalH., ClausenT., HåsethA., Lillevold,PH. (2011). Statusrapport 2010 (Seraf Rapport 4/2011) [Status report 2010]. Oslo: Senter for rus- og avhengighetsforskning, SERAF.
41.
World Health Organization (2014). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Retrieved from http//:www.who.int